Mitsubishi UFJ Kokusai Asset Management Co. Ltd. reduced its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 24.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,368 shares of the medical instruments supplier’s stock after selling 3,389 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in C.R. Bard were worth $3,277,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Athos Capital Ltd bought a new stake in shares of C.R. Bard during the second quarter valued at about $5,058,000. Schwab Charles Investment Management Inc. boosted its stake in shares of C.R. Bard by 3.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 240,591 shares of the medical instruments supplier’s stock valued at $76,054,000 after buying an additional 8,697 shares during the period. Canada Pension Plan Investment Board boosted its stake in shares of C.R. Bard by 342.3% in the second quarter. Canada Pension Plan Investment Board now owns 277,768 shares of the medical instruments supplier’s stock valued at $87,805,000 after buying an additional 214,968 shares during the period. Advisor Partners LLC boosted its stake in shares of C.R. Bard by 4.9% in the second quarter. Advisor Partners LLC now owns 1,360 shares of the medical instruments supplier’s stock valued at $430,000 after buying an additional 63 shares during the period. Finally, Palisade Capital Management LLC NJ boosted its stake in shares of C.R. Bard by 72.4% in the second quarter. Palisade Capital Management LLC NJ now owns 3,382 shares of the medical instruments supplier’s stock valued at $1,069,000 after buying an additional 1,420 shares during the period. Institutional investors and hedge funds own 85.32% of the company’s stock.

Shares of C.R. Bard, Inc. (BCR) opened at 319.75 on Friday. The company has a market capitalization of $23.24 billion, a PE ratio of 41.98 and a beta of 0.59. The firm’s 50-day moving average price is $319.00 and its 200 day moving average price is $283.44. C.R. Bard, Inc. has a 1-year low of $203.63 and a 1-year high of $323.27.

C.R. Bard (NYSE:BCR) last released its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating analysts’ consensus estimates of $2.84 by $0.08. The firm had revenue of $979.70 million during the quarter, compared to analyst estimates of $976.53 million. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the business earned $2.54 EPS. Equities analysts predict that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were given a dividend of $0.26 per share. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. C.R. Bard’s dividend payout ratio (DPR) is currently 13.67%.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/mitsubishi-ufj-kokusai-asset-management-co-ltd-sells-3389-shares-of-c-r-bard-inc-bcr/1481339.html.

Several equities research analysts recently issued reports on the company. BidaskClub cut C.R. Bard from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. Zacks Investment Research cut C.R. Bard from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $317.00 price target on shares of C.R. Bard in a research note on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $285.67.

In other news, insider John P. Groetelaars sold 23,687 shares of the business’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the transaction, the insider now directly owns 31,445 shares in the company, valued at approximately $10,022,464.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.80% of the stock is owned by insiders.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.